Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis

被引:0
作者
Cristina Fernandez-Carbonell
Leigh E. Charvet
Lauren B. Krupp
机构
[1] Northwell Health,Cohen’s Children Medical Center
[2] NYU Langone Pediatric Multiple Sclerosis Center,undefined
来源
Pediatric Drugs | 2021年 / 23卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Pediatric-onset multiple sclerosis (POMS), representing approximately 5% of all MS cases, affects the central nervous system during its ongoing development. POMS is most commonly diagnosed during adolescence but can occur in younger children as well. For pediatric patients with MS, it is critical to manage the full impact of the disease and monitor for any effects on school and social functioning. Disease management includes not only disease-modifying therapies but also strategies to optimize wellbeing. We review the interventions with the highest evidence of ability to improve the disease course and quality of life in POMS. High levels of vitamin D and a diet low in saturated fat are associated with lower relapse rates. Exercise ameliorates fatigue and sleep. Behavioral strategies for sleep hygiene and mood regulation can also improve fatigue and perceived health. POMS management should be addressed holistically, including assessing overall symptom burden as well as the psychological and functional impact of the disease.
引用
收藏
页码:317 / 329
页数:12
相关论文
共 675 条
[1]  
Ghezzi A(1997)Multiple sclerosis in childhood: clinical features of 149 cases Mult Scler. 3 43-46
[2]  
Deplano V(2002)Early onset multiple sclerosis: a longitudinal study Neurology 59 1006-1010
[3]  
Faroni J(2009)Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States Mult Scler. 15 627-631
[4]  
Grasso MG(2013)Long-term outcome of paediatric-onset multiple sclerosis: a population-based study J Neurol Neurosurg Psychiatry. 84 141-147
[5]  
Liguori M(2014)Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years Mult Scler Relat Disord. 3 186-193
[6]  
Marrosu G(2013)Pediatric multiple sclerosis: pathobiological, clinical, and magnetic resonance imaging features Neuroimaging Clin N Am. 23 227-243
[7]  
Boiko A(2020)Improved relapse recovery in paediatric compared to adult multiple sclerosis Brain 143 2733-2741
[8]  
Vorobeychik G(2019)Long-term disability progression of pediatric-onset multiple sclerosis Neurology 92 e2764-e2773
[9]  
Paty D(2014)Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network Mult Scler. 20 1502-1510
[10]  
Devonshire V(2019)Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG Neurology 92 e2538-e2549